Artios Pharma is pioneering next-generation oncology medicines that exploit DNA damage response (DDR) mechanisms to selectively destroy hard-to-treat tumors. Its lead asset, the ATR inhibitor alnodesertib, has produced durable responses across eight solid tumor types, particularly in ATM-deficient cancers where no approved therapies currently exist. The company’s second clinical candidate, ART6043, is a DNA Polymerase θ inhibitor intended for BRCA-mutant, HER2-negative breast cancer patients eligible for PARP inhibitors, while additional pre-clinical programs include DDRi-antibody drug conjugates. Proceeds from the latest financing will broaden Phase 2 studies of alnodesertib in second-line pancreatic and third-line colorectal cancers—indications recently granted FDA Fast Track status—and will fund a randomized Phase 2 trial of ART6043. Management, led by newly appointed CEO Mike Andriole, believes these efforts will accelerate both assets toward registration. Following the $115 million Series D, the company is well-capitalized to advance its pipeline and transition toward commercial readiness.

Total raised

$383M

Funding rounds

4

Latest round

Series D

Latest activity

Nov 2025